期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 156, 期 -, 页码 65-79出版社
ELSEVIER
DOI: 10.1016/j.addr.2020.06.021
关键词
-
资金
- NIH [EB000244, DE013023, EB027717-01A1]
- Ruth L. Kirschstein NRSA post-doctoral fellowship from NIBIB [1F32EB025688-01A1]
- Prostate Cancer Foundation Young Investigator Award
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZIAEB000093] Funding Source: NIH RePORTER
To develop new therapeutics involves the interaction of multiple disciplines to yield safe, functional devices and formulations. Regardless of drug function and potency, administration with controlled timing, dosing, and targeting is required to properly treat or regulate health and disease. Delivery approaches can be optimized through advances in materials science, clinical testing, and basic biology and immunology. Presently, laboratories focused on developing these technologies are composed of, or collaborate with, chemists, biologists, materials scientists, engineers, and physicians to understand the way our body interacts with drug delivery devices, and how to synthesize new, rationally designed materials to improve targeted and controlled drug delivery. In this review, we discuss both device-based and micro/nanoparticle-based materials in the clinic, our biologic understanding of how our immune system interacts with these materials, how this diverse set of immune cells has become a target and variable in drug delivery design, and new directions in polymer chemistry to address these interactions and further our advances in medical therapeutics. (C) 2020 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据